March 20-21, 2026 • Kostis Palamas Building, Athens
Click a topic to highlight related talks
Local Organising Committee
Uppsala, Sweden
Amyloid diagnosis and typing with different modalities
Milan, Italy
A one-slide approach for renal amyloid detection and typing
Limoges, France
Detecting and Sequencing Immunoglobulin Variable Domains: A MS Beginner's Perspective
Sponsor Presentation
Standardizing High-throughput LC-MS based proteomics for actionable insights; Examples from amyloid research
Gdańsk, Poland
Beyond Canonical FASTA: Variant-Aware Proteomics Revealed by ALICE-DB
London, UK
Thoughts on variant searches
Kiel, Germany
Canonical Disease Progression in Cardiac Amyloidosis
Athens, Greece
Proteomic Profiling Deciphers the Mechanisms of Cardiotoxicity in Light Chain Amyloidosis
Odense, Denmark
Diagnostic Amyloid Proteomics in Practice: Insights from the Odense Amyloidosis Center, DK
Athens, Greece
Discussing needs and resources of the network to ensure quality and perform validation of proteomic amyloid typing assays
Pisa, Italy (Online)
AmiloProteo v1.0.0 — Implementation and certification of a software for automated diagnosis and quality control
London, UK
Heavy Chain in Amyloid
Athens, Greece
Clinical cases in Athens
New York, USA
Incidental amyloid findings during joint replacement – difficulty with typing, clinical significance, next steps
Gent, Belgium
Unsolved and difficult cases
Tokyo, Japan
Amyloid typing in Japan: AL and light chain deposition disease
Rochester, USA
Dual amyloidoses – discussion of recently published manuscript, with emphasis on importance of careful and selective microdissection
Pavia, Italy
Amyloid heterogeneity: how much do we miss upon fibril extraction and proteomic analysis?
Padova, Italy
Role of alpha-synuclein truncations in Parkinson disease
Boston, USA
N-glycosylation of antibody light chains in AL amyloidosis
Rochester, USA
Mayo Clinic experience with discovery and validation of new amyloid types (ALECT2, AEnf, AEFEMP1, AApoCII, ASom (Somatostatin), AIL1RAP (Anakinra)) – what is sufficient evidence?
Boston, USA
Gelsolin domain 4 variants associated with potentially novel forms of AGel amyloidosis
All Speakers & Attendees
Interactive discussion on key topics, challenges, and future directions in amyloid proteomics
All Participants
Local Organising Committee